FindTrial
Sign In

The control study of mirtazapine and agomelatine on insomnia symptoms in patients with major depressive disorder

The effects of mirtazapine and agomelatine on insomnia symptoms in patients with major depressive disorder: a resting-state fMRI study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17013734
Enrollment
Unknown
Registered
2017-12-06
Start date
2015-06-01
Completion date
Unknown
Last updated
2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder

Interventions

Two groups:mirtazapine versus agomelatine

Sponsors

Peking University Sixth Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients were diagnosed as Major Depressive Disorder according to: 1. Aged 18-60 years; 2. Dextromanuality; 3. Female or male; 4. The total scores of HAMD =18, the total sleep syndrome scores =3; 5. Signed the ICF.

Exclusion criteria

Exclusion criteria: 1. Suicide history, allergic history for the investigated drug; 2. Combined severe or unstable somatic disease; 3. The patients were diagnosed as epilepsy, bipolar disorder, drug or alcohol dependence; 4. The patients had accepted MECT now or took antidepressants/ antipsychotics/ emotional stabilizer during last 30 days; 5. The patients had some contraindications that limit them from taking MR examination; 6. Pregnant or lactational patients; 7. Epilepsy history, COPD, restless legs syndrome, periodic legs, apnea; 8. NMS history; 9. Treatment resistant depression; 10. Contraindications for MRI scan.

Design outcomes

Primary

MeasureTime frame
PSG;MRI;—

Countries

China

Contacts

Public ContactMi Weifeng

Peking University Sixth Hospital

miwf2007@126.com+86 13811403389

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026